A RANDOMIZED, DOUBLE-BLIND, PHASE 2 PILOT STUDY OF VLX-1005 VERSUS PLACEBO IN PARTICIPANTS WITH SUSPECTED HEPARIN INDUCED THROMBOCYTOPENIA TREATED WITH BACKGROUND STANDARD OF CARE